Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer

被引:37
作者
Krishnaiah, YSR [1 ]
Satyanarayana, V
Kumar, BD
Karthikeyan, RS
机构
[1] Andhra Univ, Dept Pharmaceut Sci, Visakhapatnam 530003, Andhra Pradesh, India
[2] Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India
关键词
celecoxib; chemoprevention; colon cancer; colon targeting; guar gum; in vitro dissolution;
D O I
10.1080/10611860290022697
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The nonsteroidal anti-inflammatory drugs (NSAIDs) are found to be potential chemopreventive agents of colorectal cancer. Celecoxib, an NSAID with selective cyclooxygenase-2 inhibition, was proved to be effective for the prevention of colon cancer in patients with familial adenomatous polyposis (FAP) and sporadic polyps. In the light of this information, the present study was carried out to develop oral colon-targeting drug delivery systems for celecoxib using guar gum as a carrier. Matrix tablets containing various proportions of guar gum were prepared by wet granulation technique using starch paste as a binder. The tablets were evaluated for hardness, drug content and were subjected to in vitro drug release studies. The amount of celecoxib released from the matrix tablets at different time intervals was estimated by a HPLC method. Guar gum matrix tablets released only 2-4% of celecoxib in the physiological environment of stomach and small intestine depending on the proportion of guar gum used in the formulation. When the dissolution study was continued in simulated colonic fluids (rat caecal content medium), the matrix tablets containing 20% of guar gum released another 37% of celecoxib after degradation by the colonic bacterial action. The matrix tablets containing 30% of guar gum released about 24% of celecoxib in simulated colonic fluids indicating the susceptibility of the guar gum formulations to the rat caecal contents. The results of the study show that the matrix tablets containing either 20 or 30% of guar gum are most likely to target celecoxib for local action in the colon. The guar gum matrix tablets of celecoxib showed no change either in physical appearance, drug content or in dissolution pattern after storage at 40degreesC/RH 75% for 6 months. Differential scanning calorimetry (DSC) studies indicated no possibility of interaction between celecoxib and guar gum/other formulation excipients.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 43 条
[1]   AN EVALUATION OF PECTIN AS A CARRIER FOR DRUG TARGETING TO THE COLON [J].
ASHFORD, M ;
FELL, J ;
ATTWOOD, D ;
SHARMA, H ;
WOODHEAD, P .
JOURNAL OF CONTROLLED RELEASE, 1993, 26 (03) :213-220
[2]   STUDIES ON PECTIN FORMULATIONS FOR COLONIC DRUG-DELIVERY [J].
ASHFORD, M ;
FELL, J ;
ATTWOOD, D ;
SHARMA, H ;
WOODHEAD, P .
JOURNAL OF CONTROLLED RELEASE, 1994, 30 (03) :225-232
[3]  
Boolbol SK, 1996, CANCER RES, V56, P2556
[4]   UP-REGULATION OF CYCLOOXYGENASE-2 GENE-EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND ADENOCARCINOMAS [J].
EBERHART, CE ;
COFFEY, RJ ;
RADHIKA, A ;
GIARDIELLO, FM ;
FERRENBACH, S ;
DUBOIS, RN .
GASTROENTEROLOGY, 1994, 107 (04) :1183-1188
[5]  
Geis GS, 1999, J RHEUMATOL, V26, P31
[6]   TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS [J].
GIARDIELLO, FM ;
HAMILTON, SR ;
KRUSH, AJ ;
PIANTADOSI, S ;
HYLIND, LM ;
CELANO, P ;
BOOKER, SV ;
ROBINSON, CR ;
OFFERHAUS, GJA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) :1313-1316
[7]   Primary care:: Chemoprevention of colorectal cancer [J].
Jänne, PA ;
Mayer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (26) :1960-1968
[8]   Aspirin-like molecules that covalently inactivate cyclooxygenase-2 [J].
Kalgutkar, AS ;
Crews, BC ;
Rowlinson, SW ;
Garner, C ;
Seibert, K ;
Marnett, LJ .
SCIENCE, 1998, 280 (5367) :1268-1270
[9]  
Kawamori T, 1998, CANCER RES, V58, P409
[10]   Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers [J].
Krishnaiah, YSR ;
Satyanarayana, S ;
Prasad, YVR ;
Rao, SN .
JOURNAL OF CONTROLLED RELEASE, 1998, 55 (2-3) :245-252